Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Research output: Contribution to journalArticle

Standard

Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. / Albiges, Laurence; Powles, Tom; Staehler, Michael; Bensalah, Karim; Giles, Rachel H.; Hora, Milan; Kuczyk, Markus A.; Lam, Thomas B.; Ljungberg, Börje; Marconi, Lorenzo; Merseburger, Axel S.; Volpe, Alessandro; Abu-Ghanem, Yasmin; Dabestani, Saeed; Fernández-Pello, Sergio; Hofmann, Fabian; Kuusk, Teele; Tahbaz, Rana; Bex, Axel.

In: European Urology, Vol. 76, No. 2, 2019, p. 151-156.

Research output: Contribution to journalArticle

Harvard

Albiges, L, Powles, T, Staehler, M, Bensalah, K, Giles, RH, Hora, M, Kuczyk, MA, Lam, TB, Ljungberg, B, Marconi, L, Merseburger, AS, Volpe, A, Abu-Ghanem, Y, Dabestani, S, Fernández-Pello, S, Hofmann, F, Kuusk, T, Tahbaz, R & Bex, A 2019, 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma', European Urology, vol. 76, no. 2, pp. 151-156. https://doi.org/10.1016/j.eururo.2019.05.022

APA

CBE

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A. 2019. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. European Urology. 76(2):151-156. https://doi.org/10.1016/j.eururo.2019.05.022

MLA

Vancouver

Author

Albiges, Laurence ; Powles, Tom ; Staehler, Michael ; Bensalah, Karim ; Giles, Rachel H. ; Hora, Milan ; Kuczyk, Markus A. ; Lam, Thomas B. ; Ljungberg, Börje ; Marconi, Lorenzo ; Merseburger, Axel S. ; Volpe, Alessandro ; Abu-Ghanem, Yasmin ; Dabestani, Saeed ; Fernández-Pello, Sergio ; Hofmann, Fabian ; Kuusk, Teele ; Tahbaz, Rana ; Bex, Axel. / Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. In: European Urology. 2019 ; Vol. 76, No. 2. pp. 151-156.

RIS

TY - JOUR

T1 - Updated European Association of Urology Guidelines on Renal Cell Carcinoma

T2 - European Urology

AU - Albiges, Laurence

AU - Powles, Tom

AU - Staehler, Michael

AU - Bensalah, Karim

AU - Giles, Rachel H.

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Lam, Thomas B.

AU - Ljungberg, Börje

AU - Marconi, Lorenzo

AU - Merseburger, Axel S.

AU - Volpe, Alessandro

AU - Abu-Ghanem, Yasmin

AU - Dabestani, Saeed

AU - Fernández-Pello, Sergio

AU - Hofmann, Fabian

AU - Kuusk, Teele

AU - Tahbaz, Rana

AU - Bex, Axel

PY - 2019

Y1 - 2019

N2 - Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

AB - Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

KW - Cabozantinib

KW - Guidelines

KW - Immune checkpoint inhibitors

KW - Ipilimumab

KW - Metastatic

KW - Nivolumab

KW - Pazopanib

KW - Renal cell carcinoma

KW - Sunitinib

U2 - 10.1016/j.eururo.2019.05.022

DO - 10.1016/j.eururo.2019.05.022

M3 - Article

VL - 76

SP - 151

EP - 156

JO - European Urology

JF - European Urology

SN - 1873-7560

IS - 2

ER -